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Research Article
An allostatic mechanism for M2 pyruvate kinase as
an amino-acid sensor
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We have tested the effect of all 20 proteinogenic amino acids on the activity of the M2
isoenzyme of pyruvate kinase (M2PYK) and show that, within physiologically relevant
concentrations, phenylalanine, alanine, tryptophan, methionine, valine, and proline act
as inhibitors, while histidine and serine act as activators. Size exclusion chromatography
has been used to show that all amino acids, whether activators or inhibitors, stabilise
the tetrameric form of M2PYK. In the absence of amino-acid ligands an apparent tetra-
mer–monomer dissociation Kd is estimated to be ∼0.9 mM with a slow dissociation rate
(t1/2∼15 min). X-ray structures of M2PYK complexes with alanine, phenylalanine, and
tryptophan show the M2PYK locked in an inactive T-state conformation, while activators
lock the M2PYK tetramer in the active R-state conformation. Amino-acid binding in the
allosteric pocket triggers rigid body rotations (11°) stabilising either T or R states. The
opposing inhibitory and activating effects of the non-essential amino acids serine and
alanine suggest that M2PYK could act as a rapid-response nutrient sensor to rebalance
cellular metabolism. This competition at a single allosteric site between activators and
inhibitors provides a novel regulatory mechanism by which M2PYK activity is finely
tuned by the relative (but not absolute) concentrations of activator and inhibitor amino
acids. Such ‘allostatic’ regulation may be important in metabolic reprogramming and
influencing cell fate.
Introduction
In the 1920s, Otto Warburg observed that cancer cells produce ATP mainly through the glycolytic
pathway, rather than oxidative phosphorylation, even under aerobic conditions [1]. This metabolic
reprogramming favours proliferation of tumour cells by supporting metabolite synthesis and the accu-
mulation of biomass [2,3]. The M2 isoenzyme of pyruvate kinase (M2PYK) has been shown to play
important roles in metabolic reprogramming during cancer cell proliferation [4–6] and is a potential
cancer therapeutic target [7,8]. The altered metabolic requirements of cancer cells are necessitated by
periods of both quiescence and rapid growth. In the present paper, we introduce the idea that meta-
bolic enzymes can act as ‘allostatic’ regulators with the ability to sense and react to fluctuations in the
nutrient environment. We use the biological definition of allostasis to describe responses or mechan-
isms whereby the cell (or organism) accommodates changes (e.g. stress, nutrition) in readiness for
adopting or moving to a different state (e.g. cell division) [9]. These changes are subtly different from
homeostatic responses that react to changes in cell state to restrain or return the cell to its standard
state (e.g. using feedback mechanisms) [9].
Pyruvate kinases (PYKs) catalyse the last step of the glycolytic pathway by transferring a phospho
group from phosphoenolpyruvate (PEP) to ADP, thereby generating pyruvate and ATP. There are
four PYK isoforms found in mammals: alternative RNA splicing allows the PKLR gene to encode
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LPYK in the liver and RPYK in red blood cells [10], while alternative RNA splicing of the PKM gene gives the
M2PYK isoform, which is found in growing and dividing cells and the M1PYK (M1 isoenzyme of pyruvate
kinase) isoform which is found in muscle tissues. M1PYK and M2PYK differ by only 22 amino acids (on the
C–C interfaces, shown in Figure 1, highlighted in red) [11]. Each subunit of this homotetramer (Figure 1) con-
sists of four domains: A, B, C, and N-terminal. The A-domain and C-domain correspond to the rigid body
core of PYK. The active site is formed by a pocket between the rigid body core and the flexible B-domain.
M1PYK is the constitutively active form of the enzyme and despite the high (96%) overall sequence identity,
M2PYK has a low basal activity but is activated by the allosteric effector fructose 1,6-bisphosphate (FBP) [12].
Structural studies of M1 and M2PYK show that the 22 different residues on the C–C interface form part of the tight
inter-subunit interface, and facilitate the dissociation of M2PYK from an active tetramer to inactive monomers [13].
Monomers of M2PYK have been shown to translocate into the cell nucleus [14] and potentially act as protein
kinases to affect transcription [15]. Regulatory post-translational modifications have been shown for M2PYK but
not for M1PYK. For example, phosphorylation of residue Tyr105 inhibits tetramer formation of M2PYK [16], and
Cys358 oxidation inhibits M2PYK activity and promotes the metabolic changes required for proliferation [17].
Acetylation of Lys305 inhibits M2PYK activity [18], and acetylation of Lys433 affects FBP binding and thus prevents
M2PYK activation [19]. Hydroxylation of Pro403 and Pro408 promotes HIF-1 transactivation in cancer cells [20].
A chemically diverse collection of natural products and synthetic drug-like compounds have been shown to
modulate M2PYK activity [13,21–27] and stimulate [13] or inhibit cell growth [23,28]. Regulatory effects of
amino acids on the constitutively fully active M1PYK have been extensively studied [29–37]. The results
showed that only phenylalanine moderately regulates M1PYK by a non-competitive inhibition of its enzymatic
activity [29,33]. All the other amino acids have little direct regulatory effects on M1PYK. In contrast, M2PYK
Figure 1. Crystal structure of M2PYK.
M2PYK is a homotetramer that consists of an A-domain (green, residues 44–116 and 219–402); B-domain (cyan, residues
117–218); C-domain (yellow, residues 403–531); and N-terminal domain (blue, residues 13–43. Residues 1–12, as well as
additional residues from the His6-tagged construct that were too disordered to be solved and shown in the structures). The only
unconserved region between M1PYK and M2PYK is highlighted in red. Positions of the active site, the amino-acid binding
pocket, and the FBP-binding pocket are also highlighted. The large (A–A) and small (C–C) interfaces are shown as dashed lines.
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is known to respond to a wider range of effector molecules such as the inhibitory effect of phenylalanine [13]
and activating effect of serine [24]. An interesting link has been shown between the level of expression of
M2PYK and over 30 proteins which regulate amino-acid synthesis and metabolism [38]. Low M2PYK levels
were shown to correlate with high levels of glutamic acid and glutamine but with low levels of seven other
amino acids including histidine and serine, leading to the suggestion that PYK is a dosage-dependent regulator
of cellular amino-acid homeostasis [39].
Here, we systematically investigated the effects of all 20 proteinogenic amino acids on M1PYK and M2PYK.
A series of co-crystal complexes show that the amino acids bind in an allosteric pocket (found in both M1PYK
and M2PYK; Figure 1). Differences in side chain interactions explain how all amino acids stabilise the tetra-
meric form of M2PYK and further show how they can stabilise either the inactive T-state (phenylalanine,
alanine, tryptophan) or the active R-state (serine, histidine). Analytical gel chromatography and ELISA
(enzyme-linked immunosorbent assay) were used to investigate the time-dependent dissociation of M2PYK
and the stabilising effect of amino acids on the tetrameric form. These biochemical and biophysical stability
studies along with the X-ray structures provide a molecular mechanism for allosteric regulation of M2PYK
which is used by the cell to measure the level of nutrient. The fast (T to R allosteric switch) or slow (tetramer–
monomer dissociation) responses of M2PYK provide molecular mechanisms which can be used by the cell to
balance the rate of catabolism against nucleic acid and phospholipid anabolism as required for (cancer) cell
proliferation [5,6]. Proliferating tumour cells undergo large fluctuations in nutrients depending on the stage of
cell cycle and the local environment. We show here how M2PYK can act as an ‘allostatic’ regulator’ allowing
the cell to adapt to changes in metabolite concentrations during stages in cell growth and cell division that
require supplies of amino acids for protein and DNA production and at the same time require a regulated
supply of pyruvate for ATP production. The unique competitive allosteric inhibitory and activating effects of
the amino acids on M2PYK enzyme activity depend on their relative (rather than absolute) concentrations.
Thus, the effect of amino-acid inhibitors (e.g. Ala and Phe) even at relatively high concentrations can be
trumped by high concentrations of activators and vice versa. In contrast, relatively low concentrations of just
one activator (or inhibitor) in the absence of a competing signal will control enzyme activity. The enzymatic
response of M2PYK to these multiple complex signals provides the cell with an allostatic mechanism to facili-
tate changes required to adapt to either rapidly dividing or senescent states.
Experimental procedures
Expression and purification of human PYKs
Protein expression and purification were performed as described previously [13] with minor modifications. In
brief, cDNA encoding human M1PYK and M2PYK with N-terminal His tags were codon-optimised for
Escherichia coli expression and inserted into pET28a vectors. Afterwards, competent E. coli cells BL21(DE3)
(from Novagen, Madison, WI) were transformed with these recombinant plasmids. Cells were grown in 2×
tryptone yeast extract (tryptone and yeast extract were from Formedium, Hunstanton, U.K.) until an OD600 of
0.8–1.0, followed by a cold shock at 4°C for 1 h. The expression was induced at 18°C with 1 mM
isopropyl-β-D-thiogalactopyranoside (purchased from Melford, Ipswich, U.K.). All media were provided with
50 mg/ml kanamycin (Melford). The cells were harvested, followed by lysing with a constant cell disruption
system in lysis buffer [50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole (pH 8.0), and one one EDTA-free
protease inhibitor tablet per 5 g of cell mass (from Roche, Welwyn Garden City, U.K.)] at 25 MPa. The lysate
was centrifuged at 10°C for 45 min, and the supernatant was filtered through a 0.2-mm syringe filter. The
supernatant was purified with an immobilised metal affinity HiTrap HP Sepharose column (precharged with
cobalt), followed by a size-exclusion step with a Superdex 200 10/300GL column (all chromatography columns
used in the present study were purchased from GE Healthcare Life Sciences, Buckinghamshire, U.K.) in
Dulbecco’s PBS without calcium and magnesium [Dulbecco’s phosphate-buffered saline without calcium and
magnesium (PBS-CM), from Sigma–Aldrich, Dorset, U.K.]. His6M1/2PYKs were concentrated to 20 mg/ml
using a Vivaspin column (molecular mass cut-off, 30 kDa, from Sartorius, Goettingen, Germany) and stored at
−80°C after flash-freezing in liquid nitrogen.
Measurement of PYK activity
For the identification of PYK activity modulators, enzymatic activity assays were performed as follows. A 1.9 ml
aliquot of 20 mg/ml M1 or M2PYK in PBS-CM was added individually into 5 ml of different amino acids at
© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 1823
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5 mM in PBS-CM at pH 7.4 followed by an incubation at 37°C for 10 min. Then, the same volume of assay
buffer [PBS-CM supplemented with 10 mM MgCl2, 100 mM KCl, 1 mM NADH, 40 mmol/min ml lactate
dehydrogenase (LDH), as well as sub-saturating substrates PEP (1 mM) and ADP (0.8 mM)] was added into
the protein solution and mixed (so the concentrations of all reagents were halved). The decrease in absorbance
at 340 nm (the absorbance of NADH) was measured for 5 min at 37°C using a plate reader. PEP, ADP, LDH,
NADH, FBP and all amino acids were from Sigma–Aldrich.
For the determination of kinetics of M2PYK in the absence/presence of amino acid modulators, enzymatic
activity assays were performed as follows. A 5 ml aliquot of 0.002 mg/ml M2PYK in PBS-CM was incubated
with different concentrations of amino acids in PBS-CM supplemented with 1 mM dithiothreitol at 37°C at pH
7.4 for 10 min. Then, the same volume of assay buffer [PBS-CM supplemented with 10 mM MgCl2, 100 mM
KCl, 1 mM NADH, 40 mmol/min ml LDH, as well as saturating ADP (4 mM) and titrated substrate PEP
(0.15–10 mM)] was added. Binding affinities of amino acid ligands (alanine, phenylalanine, tryptophan, and
serine) against M2PYK were determined in the presence of a sub-saturating concentration of PEP (0.5 mM)
and ADP (0.4 mM). For these uncompetitive inhibitors the Ki values were calculated to be equal to IC50/2.
To investigate the competition between serine (activator) and alanine/phenylalanine (inhibitors), M2PYK
was incubated with mixtures of serine and alanine (or serine and phenylalanine) over a range of different con-
centrations under the same condition described above. The decrease in absorbance at 340 nm was measured
for 5 min at 37°C using a plate reader.
Values of the kinetic parameters (Vmax, K0.5(PEP), and nH) were determined by fitting the equation below to
the data.
V ¼ Vmax  ½PEP
nH
KnH0:5 þ ½PEPnH
The Lineweaver–Burk plots were fit using the equation below:
Y ¼ K
nH
0:5 þ (1=x)nH
Vmax  (1=x)nH
The Berkley Madonna software (http://www.berkeleymadonna.com/) was used to model approximate propor-
tions of monomer and tetramer M2PYK at given total protein concentrations. The calculation was based on a
simplified tetramer [T] monomer [M] equilibrium:
[T]O [M]þ [M]þ [M]þ [M]with Kd ¼ [M]4=[T]
Monitoring the rate of loss of enzyme activity gave an estimated half-life (t1/2) of ∼15 min and a dissociation
rate constant (koff = 0.69/t1/2) of ∼10−3 s−1. The association rate constant was scaled to give a Kd of 0.9 mM,
which was estimated from analytical gel chromatography results.
Analytical gel chromatography
Analytical gel chromatography was performed to characterise the oligomerisation/dissociation of M2PYK in
the presence/absence of different amino acids. Aliquots of 400 ml of 0.1 mg/ml purified M2PYK were incubated
with or without 10 mM amino acids in PBS-CM at room temperature at pH 7.4 overnight. After the incuba-
tion, samples were loaded independently onto a Superdex 200 PC 3.2/30 gel-filtration column. Samples of
25 ml were injected, and the column flow rate was maintained at 0.1 ml/min. Protein peaks were monitored
using the absorbance at both 280 and 214 nm. The retention volumes for the M2PYK peaks were the same as
those identified by SEC-MALS as monomer and tetramer peaks (using the same Superdex 200 column) in our
previous study [13].
Enzyme-linked immunosorbent assay
For the production of specific antibodies, a peptide immunogen (Supplementary Figure S1) specific for
M2PYK was covalently conjugated with the carrier protein BSA, and injected into Balb/c female mice (6–7
weeks) at 2-week intervals. A mouse showing best selectivity for M2PYK was chosen as a spleen donor. After
© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).1824
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the production of a hybridoma, a cell line secreting a specific monoclonal antibody was screened and expanded.
The specific monoclonal antibody against M2PYK was identified, purified and conjugated with horseradish per-
oxidase (HRP) for further ELISAs.
A stock solution of anti-His-tag antibody in carbonate buffer (pH 9.6) was coated onto wells at 50 ml/well
at 4°C overnight. The wells were then blocked with 100 ml/well of PBS/Tween 20/3% BSA for 1 h at room
temperature. Titrated M2PYK (2.5–0.0039 mg/ml) was incubated with or without ligands (10 mM for all amino
acids and 1 mM for FBP) in PBS/Tween 20/3% BSA at room temperature for 1 h. Then, 100 ml of the solution
was added to each prepared well for an incubation of 1 h. Afterwards, a 100 ml aliquot of PBS/Tween 20/3%
BSA containing 4 mg/ml HRP-conjugated M2PYK antibody was added to each well and incubated for 1 h at
room temperature. Electrochemiluminescence solution was added at 50 ml/well to develop the luminescence,
which was read immediately with a plate reader. Three washes with PBS/Tween 20/3% BSA were performed
between each step.
Crystallisation and data collection
Single crystals of M2PYK were obtained at 17°C by vapour diffusion using the hanging-drop technique. The
drops were formed by mixing 1.5 ml of wild-type M2PYK (20 mg/ml) solution containing ligands with 1.5 ml
of reservoir solution (composed of 11–16% PEG 3350, 100 mM sodium cacodylate, 50 mM MgCl2, and
100 mM KCl). In addition, 20 mM L-alanine was added for the co-crystallisation of M2PYK/Ala crystals;
50 mM L-phenylalanine was added for M2PYK/Phe crystals; 100 mM L-serine, 1 mM oxalate, and 1 mM ATP
were added for M2PYK/Ser crystals; 30 mM L-tryptophan was added for M2PYK/Trp crystals. The pH for
obtaining optimal crystals was 7.2–7.8. Before data collection, crystals were dipped in a freezing solution con-
sisting of reservoir solution supplemented with the same concentration of ligands as in the original solution, as
well as up to 35% PEG 3350, which eliminated the appearance of ice rings. Diffraction data were collected at
the Diamond synchrotron radiation facility in Oxfordshire, U.K. on beamline I03 (for the M2PYK/Ala struc-
ture), I04-1 (for the M2PYK/Phe and the M2PYK/Trp structures), and I24 (for the M2PYK/Ser structure). All
datasets were obtained from a single crystal flash-frozen in liquid nitrogen. A more detailed description and
discussion of the crystallisation trials is in the Supplementary Material.
Structure determination
All four M2PYK structures were solved by molecular replacement using the program PHASER [40]. A
monomer (Chain A) from the previously determined tetrameric structure of M2PYK (in R-state, PDB ID:
4B2D) served as the search model for the M2PYK/Ser structure. Chain A of a different M2PYK structure (in
T-state, PDB ID: 4FXJ) was used as the search model for the M2PYK/Phe, M2PYK/Ala, and M2PYK/Trp
structures. There were clear molecular replacement solutions for all structures. The resulting models were then
subjected to 10 cycles of rigid body refinement using the program REFMAC [41]. Afterwards, manual changes
were made to models to adjust side chain conformations and to add additional residues to the N terminus
using COOT [42]. The models were then subjected to several rounds of translation libration screw refinement
and restrained refinement, and ligand molecules were added where clear unbiased Fo–Fc electron density was
observed. Water molecules were added to the model using COOT, and after several rounds of restrained refine-
ment, R/Rfree values converged. Data collection and refinement statistics are summarised in Table 1.
Results
Time-dependent dissociation of M2PYK tetramers
Gel filtration traces of M2PYK show two distinct peaks corresponding to the tetramer and the monomer
(Figure 2A). The ratio of tetramer to monomer is concentration-dependent with higher concentrations
favouring the tetrameric state. In this experiment, the time-dependent dissociation of M2PYK was measured
by diluting a solution of 20 mg/ml M2PYK to 0.1 mg/ml (in PBS-CM, pH 7.4) and incubating for 0, 1, 2,
5.5, 8, and 12 h at room temperature (Supplementary Figure S2). The results indicate that M2PYK disso-
ciated slowly from tetramer to monomer, reaching an equilibrium of 1 tetramer: 4 monomers after many
hours. These gel filtration studies, carried out at different concentrations [13], also provide an estimate of a
tetramer to monomer dissociation constant. Supplementary Figure S2 shows gel filtration traces for an
M2PYK sample with a total protein concentration of 1.8 mM which after equilibration shows an equal (50:50
by mass) concentration of monomers (0.9 mM) and tetramers (0.23 mM). These equilibrium values are
© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 1825
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consistent with an apparent M2PYK tetramer–monomer dissociation constant of 0.9 mM. A similar experi-
ment was carried out with the M1PYK isoform and showed no dissociation of the tetrameric form
(Figure 2B). Gel filtration studies can only provide reliable signal at relatively high protein concentrations
greater than ∼0.1 mg/ml. M1/M2PYK concentrations in normal and cancerous cells have been estimated at
values between 0.005 and 2.6 mg/ml (Supplementary Figure S3) [38], which bracket the concentrations used
for the gel filtration experiments.
Table 1 Data collection and refinement statistics
M2PYK/Ala M2PYK/Phe M2PYK/Trp M2PYK/Ser
Data collection
Space group P 21 21 21 P 1 21 1 P 1 21 1 P 1
Cell dimensions
a, b, c (Å) 160.72, 199.36,
243.23
97.37, 70.34,
168.64
96.88, 70.58,
168.50
93.35, 108.94,
124.34
α, β, γ (°) 90.00, 90.00, 90.00 90.00, 106.06,
90.00
90.00, 106.02,
90.00
89.72, 71.13,
66.94
Wavelength (Å) 0.9763 0.91741 0.91741 0.97625
Resolution1 (Å) 199.33–3.72 (3.82–
3.72)
71.88–2.46 (2.524–
2.46)
72.54–3.20 (3.283–
3.20)
13.24–2.96 (3.04–
2.96)
Rmerge
2 0.125 (0.832) 0.077 (0.605) 0.196 (0.845) 0.074 (0.544)
I/σI 7.5 (1.8) 14.2 (2.5) 7.5 (1.4) 8.4 (1.8)
Completeness (%) 95.3 (96.3) 98.8 (99.6) 98.2 (99.4) 98.6 (98.0)
Multiplicity 4.2 (4.3) 5.8 (5.7) 2.9 (3.0) 2.7 (2.7)
Refinement
Rwork/Rfree
3 0.2196/0.2488 0.1966/0.2246 0.2284/0.2652 0.2360/0.2516
No. atoms 46 088 14 593 14 263 31 408
Protein 45 962 14 180 14 132 31 296
Ligand/ion 126 60 104 112
Water 0 353 27 0
B-factors
Protein 138.2 63.8 59.0 93.4
Ligand/ion 118.0 68.0 61.0 94.0
Water — 54.8 18.0 —
R.m.s. deviations
Bond lengths (Å) 0.009 0.0085 0.013 0.0076
Bond angles (°) 1.299 1.272 1.496 1.163
Ramachandran plot (%)
Favoured
regions
95 98 96 95
Allowed regions 4 2 3 4
Disallowed
regions
1 0 1 1
Conformation T-state T-state T-state R-state
PDB code 6GG3 6GG4 6GG5 6GG6
1Values in parentheses are for the highest resolution shell.
2Rmerge = Σhkl|I−〈I〉|/ΣhklI.
3Rwork = Σ|Fobs−Fcalc|/Σ|Fobs|, where Fobs and Fcalc are the observed and the calculated structure factors, respectively. Rfree is calculated using 5% of
total reflections randomly chosen and excluded from the refinement.
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Many papers have shown that the M2PYK tetramer has higher activity relative to its monomeric/dimeric
forms [5,21,22,43,44]. Here, we show that loss of enzyme activity correlates with the time-dependent dissoci-
ation observed in the gel filtration experiments. In the enzyme assay (see Experimental Procedures) activities
were measured using a stock solution of 20 mg/ml M2PYK which was diluted to a concentration of 0.002 mg/
ml in PBS-CM (pH 7.4). Monitoring enzyme activity as a function of time showed a 50% loss of activity of
M2PYK in 15 min (Figure 2C). The enzyme concentration used to measure the enzyme activity is 50 times
more dilute than the solutions studied by gel filtration. An identical study with M1PYK showed only 17% loss
of M1PYK activity over the 3 h period of the experiment consistent with M1PYK retaining its active tetrameric
structure even at very low protein concentration. The time and concentration dependencies on the activity of
M2PYK also explain apparent differences with previously published results on the effect of amino acids on
M2PYK measured using end-point assays (see Supplementary Material).
Amino acids have significant effects on the activity of M2PYK but not M1PYK
Here, we show the regulatory effects of physiological amino acids on M2PYK which were compared with those of
M1PYK under the same conditions. PYKs were incubated with 2.5 mM amino acids including alanine, arginine,
asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methio-
nine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine (all L-stereoisomers) or with no
amino acid (as control). FBP was used as a positive control. The reaction was performed after pre-incubation in
the presence of sub-saturating substrates in PBS at pH 7.4 at 37°C as described in Experimental Procedures.
Many amino acids showed strong effects on M2PYK activity (Figure 3). Phenylalanine and alanine were the
most powerful inhibitors (nearly 100% inhibition) among all tested amino acids. Methionine, proline, tryptophan,
and valine were also strong inhibitors (90–65% inhibition), whereas the inhibition by isoleucine, threonine, and
cysteine was more modest (50–20% inhibition). Histidine and serine were identified as activators (∼30% activa-
tion) for M2PYK. As an extensively studied natural activator of M2PYK, FBP showed the strongest activation
among all tested ligands (∼40% activation). In contrast, M1PYK (shown in white bars) was only slightly (10%)
inhibited by phenylalanine, as well as by arginine, glycine and lysine, with all the other ligands, including FBP,
having little or no regulatory effect. These results for M1PYK compare well with previous reports [13,29,33].
Enzyme kinetics: amino acids are allosteric regulators of M2PYK
To study the effects of the amino acids as regulators of M2PYK, we performed enzyme kinetic assays for PEP
in the presence or absence of three inhibitors (phenylalanine, alanine, and tryptophan) and an activator
(serine). The kinetic curves are shown in Figure 4 and Supplementary Figure S4. Rather than the sub-saturating
concentrations of both substrates used for the modulator screening assay (Figure 3), a saturating concentration
of ADP (2 mM) was used for the kinetics assay, giving an apparent Vmax value of ∼100 mmol/min mg for
M2PYK and a K0.5[PEP] of ∼0.4 mM. As shown in Figure 4A–C, addition of either of the three inhibitors
significantly decreased Vmax and increased K0.5[PEP], with a concomitant increase in co-operativity (the Hill
Figure 2. Analytical gel-filtration and enzyme assays suggest M2PYK equilibrates between tetramer and monomer,
whereas M1PYK retains its tetrameric form.
(A and B) Analytical gel-filtration assays for M2PYK and M1PYK (incubated for 12 h at room temperature) were carried out to
determine the tetramer (left peaks): monomer (right peaks) ratio with a Superdex® 200 PC 3.2/30 gel-filtration column.
(C) Gradual activity loss of M1PYK (black) and M2PYK (orange). Data represent the mean± standard error of three experiments.
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coefficient increases from 1.0 to more than 2.0). The kinetic curves (Figure 4A–C) measured at the different
inhibitor concentrations are consistent with phenylalanine, alanine and tryptophan each acting as allosteric
uncompetitive inhibitors of M2PYK and show increasing concentrations of the PEP substrate failing to
compete out the effect of these inhibitory amino acids. Although all three tested inhibitors show a similar
inhibitory pattern on M2PYK, they have different IC50 values: alanine has the lowest IC50 of 124 mM compared
with phenylalanine (410 mM) and tryptophan (445 mM). The inhibitor constants (Ki) for alanine, phenylalan-
ine, and tryptophan are 62, 205, and 222 mM, respectively. In contrast, serine activated M2PYK by increasing
Vmax (from 106 up to 170 mmol/min mg; Figure 4D). These results suggest that enzymatic activity of intracellu-
lar M2PYK may be affected by the relative concentrations of certain amino acids in the cytosol.
Competitive effects of amino-acid activators and inhibitors at physiological
concentrations
Different concentrations of binary mixtures of serine and alanine (or phenylalanine) were used to show their
competing effects on enzyme activity (Figure 4E–F). At a concentration of 1250 mM, the activator serine
increases the IC50 values of inhibitory amino acids alanine (from 124 to 1536 mM) and phenylalanine (from
410 to 2922 mM). The reported concentrations of amino acids in normal and cancer tissues are in the high
micromolar to low millimolar range (Supplementary Figure S5) [45]. Phenylalanine at a cellular concentration
of ∼0.2 mM reduces M2PYK activity to ∼65%. This value can be raised to nearly full activity in the presence
of 0.6 mM serine (Figure 4E). With an approximate cellular concentration of alanine of 200–300 mM, M2PYK
is only ∼10% active; however, in the presence of serine at an intracellular concentration of ∼0.6 mM, activity is
restored to ∼65% (Figure 4F). An in vitro enzyme assay of M2PYK in the presence of different concentrations
of both amino acids (Figure 4E–F) shows that in normal tissue, where the intracellular concentrations of
alanine and serine are ∼0.5 and 0.6 mM, respectively, the activity of M2PYK is 109% (compared with unligated
protein). Intracellular concentrations of amino acids can vary significantly within tumours [45] with alanine
elevated up to 10-fold and serine by 2-fold compared with normal tissue. Figure 4F maps out the effect of
Figure 3. Effects of amino acids and FBP on the activity of M1PYK (□) and M2PYK (▪).
The activities of M1/M2PYK in the absence of ligands were calculated as 100%, to which the activities tested in the presence
of 2.5 mM ligands were normalised. Phenylalanine, alanine, tryptophan, methionine, valine, and proline were strong inhibitors
for M2PYK (99–65%), whereas the inhibition by isoleucine, threonine, and cysteine was more modest (50–20%). Serine and
histidine were identified as activators (higher than 120% activity) for M2PYK. The values within the dashed blue lines (100%±
20%) may be regarded as showing no significant regulation. Data represent the mean ± standard error of three experiments.
Sub-saturating concentrations of both substrates PEP (0.4 mM) and ADP (0.5 mM) were used.
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Figure 4. Effects of amino acids on M2PYK activity. Part 1 of 2
(A–D) Kinetic profiles of M2PYK determined for PEP [with saturating ADP (2 mM)] in the presence or absence of different
concentrations of phenylalanine, alanine, tryptophan, and serine. Lineweaver–Burk plots are shown in Supplementary Figure S4.
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these competing inhibitor and activator molecules on the enzyme activity of M2PYK in such an environment
and shows that, depending on the relative (and absolute) concentrations of the amino acids, activity can be
tuned from anywhere between 10 and 140%, providing a rapid mechanism for controlling the balance between
cell growth and ATP production.
ELISA and gel filtration assays show amino acids stabilise the tetramer form
of M2PYK
Analytical gel chromatography was used to investigate the effects of amino acids on the oligomerisation of
M2PYK. Briefly, 0.4 ml samples of 0.1 mg/ml of M2PYK were incubated in the absence/presence of 10 mM
alanine, phenylalanine, serine, or tryptophan in PBS-CM at pH 7.4 at room temperature for 12 h. The chroma-
tograms (Figure 5) show that not only the activator serine, but also all the inhibitory amino acids stabilised tet-
ramers over monomers. It is likely that alanine and tryptophan function by stabilising the T-state inactive
tetramer in the same manner as that previously reported for phenylalanine [13], whereas serine induces the
Figure 4. Effects of amino acids on M2PYK activity. Part 2 of 2
(E) The competing effects of serine and phenylalanine on M2PYK activity. Sub-saturating concentrations of PEP (0.4 mM) and
ADP (0.5 mM) were used for this enzyme assay. (F) The competing effects of serine and alanine on M2PYK activity. The 3D
histogram on the right shows relative in vitro enzymatic activity of M2PYK in the presence of different concentrations of
alanine/serine. The white bar is the M2PYK activity with no amino acid ligands, calculated as 100% activity. The green bar
corresponds to M2PYK activity in the presence of alanine/serine at normal intracellular concentrations, while the purple bar
corresponds to that of concentrations in cancer cells (Supplementary Figure S5). Sub-saturating concentrations of PEP
(0.4 mM) and ADP (0.5 mM) were used for this enzyme assay. Data represent the mean ± standard error of three independent
experiments.
Figure 5. Amino acids and FBP minimise M2PYK dissociation.
(A) Analytical gel chromatography for 0.1 mg/ml M2PYK incubated in PBS-CM (pH 7.4) for 12 h at room temperature
(monitored at 214 nm). (B–E) Analytical gel chromatography for 0.1 mg/ml M2PYK incubated with 10 mM serine, phenylalanine,
alanine, and tryptophan in PBS-CM (pH 7.4) for 12 h at room temperature (monitored at 214 nm). Dashed lines indicate the
positions of elution of tetramers and monomers. (F) ELISA test using an anti-M2PYK antibody that binds to its C–C interface
(shown in Figure 1). The values of luminescence reflect the amount of antibody that was bound to different concentrations of
PYK in the presence of ligands (10 mM of each amino acid) at pH 7.4.
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formation of an R-state tetramer. It has previously been shown that the M2PYK activator FBP stabilised the
tetrameric form [13]. Dissociation studies of M2PYK using SEC-MALS [13] and ultracentrifugation [46] show
the predominant forms in solution are tetramer and monomer. Size exclusion chromatography (Figure 5)
shows no obvious peak that may correspond to M2PYK dimers. Earlier literature on M2PYK frequently refers
to a tetramer–dimer equilibrium; however, all biophysical measurements in solution published to date suggest
that tetramers and monomers are the predominant species.
To investigate the effect of ligand binding on monomer–tetramer equilibrium at lower protein concentra-
tions, we developed an ELISA assay. A highly selective (M2PYK versus M1PYK) monoclonal antibody that
only binds to the C–C interface of M2PYK was produced by immunising with an epitope specific for this
region (Supplementary Figure S1). As the epitope is hidden in the tetrameric form of M2PYK, antibody
binding on the C–C interface of M2PYK reflects the amount of monomer/dimer but not tetramer. The ELISA
tests were performed using low concentrations of His6-M1/2PYK (0.0039–2.5 mg/ml) incubated with no ligand
or 10 mM of each amino acid for 1 h in PBS-CM at pH 7.4 at room temperature. The incubated solutions were
added to 96-well plates precoated with anti-His-tag antibodies. HRP-conjugated M2PYK antibodies were then
incubated, followed by luminescence reading. The results (Figure 5F) showed that the reading for M2PYK in
the absence of stabilising ligands was significantly higher than with alanine, phenylalanine, serine, and trypto-
phan. This indicates that, at low concentrations, M2PYK dissociates, thereby exposing the epitope on the C–C
interface allowing the antibody to bind. In the presence of alanine, phenylalanine, serine, or tryptophan,
M2PYK is predominantly tetrameric and the hidden epitope cannot be bound by the antibody.
Crystal structures of amino acid complexes provide a mechanism of T- to
R-state transition in M2PYK tetramers
The role of the natural effector FBP which binds 40 Å away from the active site (shown in Figure 1) of M2PYK
has been extensively studied as a promoter of the R-state tetrameric form with concomitant activation
[12,13,21,47]. Other reports have shown that M2PYK can transit into an inactive T-state tetramer [13,48].
Figure 6. T-state and R-state M2PYK structure models.
Each subunit of M2PYK is shown as an irregular pentagonal block. B-domains are represented by narrow rectangles.
Amino-acid residues and loops are shown in green. Helices are shown as cylinders. Amino-acid inhibitor and activator are
shown in orange and cyan, respectively. Important hydrogen-bonded and salt-bridge interactions are highlighted by dashed
lines. Active sites are shown in blue rectangles.
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Here, with the solution of wild-type M2PYK crystal structures co-crystallised with serine, alanine, phenylalan-
ine, or tryptophan (Table 1, Figure 7 and Supplementary Figure S6), we demonstrate how different amino acids
selectively stabilise M2PYK in tetrameric R or T states.
Table 2 Comparisons of subunit rotation angles and tetramer fits among different M2PYK
crystal structures
4FXJ: A published crystal structure with M2PYK-R489A and ligand phenylalanine.
4B2D: A published crystal structure with M2PYK/FBP/Ser.
4FXF: A published crystal structure with M2PYK/FBP.
3SRF: A published crystal structure with M1PYK.
Ala Phe Trp Ser 4FXJ 4B2D 4FXF 3SRF
Ala 3.23 3.66 9.1 3.56 9.25 9.19 9.29
Phe 1.45 0.47 11.28 0.38 11.23 11.12 11.76
Trp 1.58 0.26 11.52 0.59 11.53 11.37 12.05
Ser 3.65 4.68 4.76 11.50 0.65 1.08 1.66
4FXJ 1.49 0.38 0.60 4.68 11.40 11.25 11.99
4B2D 3.70 4.69 4.79 0.42 4.68 0.97 1.99
4FXF 3.33 4.23 4.33 0.93 4.24 0.93 2.71
3SRF 3.88 5.00 5.10 0.95 5.01 1.06 1.55
Italics: RMS fit (Å) (tetramer–tetramer best fit, calculated with Cα atoms). Bold: subunit rotation angles (°) (calculated
based on the tetramer–tetramer RMS best fit).
Figure 7. Effects of amino-acid binding on the conformation of the binding pockets.
(A–C) Binding of inhibitory amino acids phenylalanine, tryptophan, and alanine, respectively. (D) Binding of the activator serine.
(E) Comparison of the four binding conformations to highlight different structural effects of the amino acids on their binding
pockets. The hydrophobic side chains of the inhibitors alanine, phenylalanine, and tryptophan push the N-terminal loop
(residues 1–43) outwards, whereas the hydrophilic side chain of serine, an activator, stabilises the loop in an inward position by
forming a hydrogen bond with Arg43.
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R-state M2PYK/serine structure
Chaneton et al. obtained an R-state M2PYK structure in complex with serine [24] by soaking serine into an
M2PYK/FBP crystal. FBP is a strong activator and locks M2PYK in the active R-state, and crystal soaking with
serine leaves an open question as to whether the interactions made by serine are facilitated by the preformed
FBP-bound R-state structure. Here, we co-crystallised serine with M2PYK in the absence of FBP and show that
the serine interactions alone stabilise the R-state. An overlay of M2PYK/FBP (PDB ID 4FXF) with M2PYK/Ser
gives an RMS fit (4 × 407 Cα atoms) for all four subunits of 0.93 Å (Table 2). This R-state conformation of
M2PYK is very similar to the constitutively fully active M1PYK structure (RMS fit of 0.95 Å). The enhanced
activity of the serine-bound structure can therefore be explained by the stabilisation of the R-state conformation
(Figure 6) in which Arg342 from an adjacent protomer primes a glycine-rich active-site helix and locks it in a
conformation allowing substrate binding [13]. The interactions made by serine in the amino-acid binding
pocket help lock the R-state conformation which is stabilised by a well-defined arrangement of hydrogen bonds
across the C–C and A–A interfaces (Figure 6).
Inhibitory alanine, phenylalanine, tryptophan T-state structures
Co-crystal structures of M2PYK with alanine, phenylalanine, or tryptophan show the amino acids all binding
with similar poses in the amino-acid binding pocket (located between the A-domain and C-domain of each
subunit). The carboxyl groups of the amino acids form strong hydrogen bonds to the side chains of Asn70 and
Arg106, and the amino groups hydrogen-bond to the side chain of His464 and the main-chain oxygen on
Ile469 (Figure 7). They adopt a binding pose that is very similar to that observed in the activating serine struc-
ture except that the hydrophobic side chains of the three inhibitory amino acids cause a widening of the
binding pocket and make contact with the carbonyl oxygen atom from Arg43, effectively pushing away the
N-terminal strand (Figure 7). In contrast, in the serine structure the side chain hydroxyl group makes a hydro-
gen bond with the Arg43 carbonyl side chain. A T-state structure of a mutated form of M2PYK (R489A)
co-crystallised with phenylalanine has been reported previously (PDB ID: 4FXJ) [13]. The mutation (R489A)
prevents binding of FBP in the effector site. Comparison with the co-crystal structures of wtM2PYK with
phenylalanine, alanine, or tryptophan (Table 2) shows that the R-/T-state transition is regulated by amino acid
binding and is not affected by the R489A mutation.
Discussion
We have shown that the R-state M2PYK, stabilised by FBP and/or serine, adopts a very similar conformation
to the constitutively fully active M1PYK (PDB ID: 3SRF, the RMS fits for R-state structures and M1PYK are
within 1 Å; Table 2). The hydrogen-bonding patterns across the A–A and C–C interfaces are also completely
conserved between these structures (Supplementary Table S2).
As described previously [13], the R-state conformation puts Arg342 from an adjacent protomer in a position
to hydrogen-bond to backbone carbonyls of a short helical stretch (Arg294-Glu300) (Figure 6), thus shaping
and priming the active site to accept the PEP substrate molecule. Though both FBP and serine appear to act as
M2PYK ‘activators’, they are in fact simply stabilising the R-state conformation and also preventing dissociation
of the tetramer into inactive monomer or dimer forms. The enzyme activities of M2PYK measured in the pres-
ence of the activators support this picture (Figure 4D), and both Km and kcat values never improve on those of
M1PYK, which provides the ideal active conformation and seems to exist as a stable, constitutively fully active
tetramer at most biologically relevant concentrations.
The X-ray structure of the M2PYK/Ser complex shows that the attractive pull of the N-terminal domain by
the serine side chain shrinks the allosteric pocket and results in the formation of a hydrogen bond between
Thr41 and Arg500 (Figure 7D). In this active-R-state conformation, both the C–C and A–A interfaces are
zipped together by a total of 20 cross-interface hydrogen bonds (Figure 6 and Supplementary Table S2).
The T-state structure is held together by a rather different network of inter-protomer hydrogen bonds across
the C–C and A–A interfaces (Figure 6). Binding of the inhibitory phenylalanine, tryptophan, or alanine stabi-
lises the T-state structure, each protomer subunit is rotated by 11° relative to the R-state structures (Figure 6).
The X-ray structures of the inhibitory amino-acid complexes show the N-terminal strand pushed by ∼3–4 Å
compared with the R-state serine structure (Figure 7). The repulsive push from alanine, phenylalanine, or tryp-
tophan leads to an interesting hydrogen-bonding rearrangement in which four Asp24-Arg400 salt bridges stabi-
lising the C–C interface in the R-state switch partners to stabilise protomers across the A–A interface in the
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rotated T-state (Figure 6 and Supplementary Figure S7). The C–C interface in the T-state conformation is held
by hydrogen bonds between Asp487 and Trp515, with the indole side chain anchored in a pocket further
securing the T-state conformer (Figure 6 and Supplementary Figure S8).
M2PYK is critical for regulating the synthesis and metabolism of serine. Knockdown and inactivation of M1
and M2 PYK have been shown to result in a build-up of metabolites of the glycolytic pathway, enabling synthe-
sis of serine from its precursor 3-phosphoglycerate (Figure 8) [24]. In a complementary experiment, cells
treated with a synthetic M2PYK activator became dependent on serine for continued cell proliferation [49].
Together with the knowledge that binding of serine activates M2PYK, these results suggested that there is a
feedback mechanism regulated by serine concentration which provides a balance between glycolysis/ATP pro-
duction (promoted by serine-bound active M2PYK) and cell proliferation (favoured by inactive M2PYK). This
also fits with the result that M2PYK activated by FBP inhibits cell proliferation, while inhibition of M2PYK by
phenylalanine favours cell proliferation [13].
Figure 8. The regulation of M2PYK by metabolites.
M2PYK is at the intersection of metabolic pathways (shown with black arrows). Blue solid arrows show the transformation of
M2PYK among active tetramer (green), inactive tetramer (orange), and monomer (orange). Green dotted arrows show that FBP
and serine stabilise M2PYK in the active tetrameric form, and thereby activate its enzymatic activity. In contrast, phenylalanine,
tryptophan, valine, and alanine inhibit M2PYK enzymatic activity by stabilising it in an inactive tetrameric form (shown with
orange dotted arrows). Autophagic alanine secretion from neighbouring cells [51] are shown in purple.
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Measured intracellular alanine concentrations from various cell types range from 0.4 mM to over 4 mM
(Supplementary Figure S5), which are sufficient to inhibit M2PYK activity and stimulate (cancer) cell prolif-
eration. The main biosynthetic route for alanine is via alanine transaminase (ALT) using pyruvate as a sub-
strate [50], and elevated plasma levels of ALT are indeed found in cancer patients. Pancreatic ductal
adenocarcinoma tumour cells rely on alanine, which feeds the tumour and which is provided in millimolar
concentrations by autophagous pancreatic stellate cells [51]. Labelling studies further show that pyruvate gen-
erated from the transaminase feeds the tricarboxylic acid (TCA) cycle. These observations suggest that
alanine serves a double purpose of decreasing glycolytic flux (allowing metabolite build-up) and also providing
pyruvate for the TCA cycle.
The metabolic requirements of a cell committed to growth and division are very different from those of a
quiescent or senescent cell. Once the fate of the cell is set, its metabolism must be reprogrammed accordingly.
Homeostatic mechanisms that use feedback loops to maintain steady-state concentrations and activities need to
be modified to accommodate the new environment: allostatic mechanisms facilitate those required changes in
regulatory mechanisms. M2PYK therefore provides an excellent example of an allostatic regulator in which the
opposing effects of activating (serine, histidine) and inhibiting (alanine, phenylalanine, tryptophan) amino
acids provide a finely balanced feedback mechanism for tuning M2PYK activity over a wide range of absolute
and relative concentrations. With high levels of serine (or FBP), M2PYK will be turned up and the TCA cycle
will be fuelled by pyruvate from the last step in glycolysis [24]. With high levels of alanine (or phenylalanine or
tryptophan), M2PYK is turned down and the TCA cycle may be fuelled by pyruvate produced by ALT [51]
(Figure 8). Depending on the relative concentrations of serine (up to ∼1 mM) and alanine (up to ∼5 mM),
M2PYK activity can be tuned to run from 5 to 140% of its velocity (Figure 4E). The important regulatory
factor is the ratio of activating and inhibiting amino acids and not their absolute concentrations. Thus, M2PYK
can act to regulate metabolism by sensing a range of concentrations and can use these inputs to control its
enzyme activity by switching quickly (within seconds) between inactive T-state and active R-state conforma-
tions. At very low levels of amino-acid concentration (less than their Ki values) and with enzyme concentration
less than ∼2 mM, M2PYK will dissociate into enzymatically inactive monomers. Monomeric M2PYK has been
shown to enter the nucleus and promote transactivation of HIF-1 target genes [19], many of which are meta-
bolic enzymes, thus providing another regulatory mechanism for M2PYK.
The allostatic adjustments made by an organism to compensate for any adaptive change come at a cost that
is defined as ‘allostatic load’. This (usually energetic) load is related to the stress imposed on the organism
adjusting to its new state [52]. Here, we extend these ideas to encompass the allostatic load experienced by cells
that are reprogrammed for proliferation (or senescence). For example, in cancer cells, biochemical pathways
including metabolism are programmed for cell division and require a catabolic activity to match nutrient
supply. Here, we show that M2PYK can sense the relative levels of different types of nutrient and process the
various input signals to reduce the allostatic load on the cell. M2PYK is therefore able to guide the cell towards
different fates: enhanced oxidative phosphorylation (by pyruvate production) or enhanced cell growth (by accu-
mulation of other metabolites) or modified transcription patterns (by inactive monomers of M2PYK entering
the nucleus [14]).
Cellular biochemical networks for metabolism, phagocytosis, and transcription are highly interconnected via
various nodes. Regulation of the different cellular processes involves communication between the networks by
perturbing molecular concentrations of their intermediates and by modulation of reaction rates of key enzymes.
The structural and enzymatic results presented here provide a molecular description of the M2PYK metabolic
sensor mechanism that can react to widely fluctuating nutrient concentrations in the cell and deliver appropri-
ate allostatic outputs to these various biochemical processes.
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